Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL28830117 | 0.89 | TSHR (0.55) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL31149146 | 0.86 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Lactic Acid SCHEMBL232168 | 0.85 | TSHR (0.67) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Bicarbonate SCHEMBL15282245 | 0.84 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Bicarbonate SCHEMBL28272077 | 0.84 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Lactic Acid SCHEMBL28201828 | 0.83 | TSHR (0.64) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL3409457 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Benzene SCHEMBL9751882 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL30307036 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL597672 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816897-B | Preparation method of levamlodipine besylate | 常州瑞明药业有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-113816897-A | Preparation method of levamlodipine besylate | 常州瑞明药业有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | TSHR 1637/4885SMN1; SMN2 4854/4885POLB 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.